BEAM
Beam Therapeutics Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -15.4% ·
share flow +24.6% ·
net new positions -18.2%
— formula
Concentrated accumulation — rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 98 | +9 | 71.47M | $2.45B | +12 | −3 |
| Q1 2026 | 92 | +3 | 70.17M | $1.67B | +9 | −6 |
| Q4 2025 | 89 | +3 | 73.41M | $2.04B | +4 | −1 |
| Q3 2025 | 16 | -1 | 52.77M | $1.28B | +1 | −2 |
| Q2 2025 | 14 | 0 | 51.27M | $872.17M | +1 | −1 |
| Q1 2025 | 11 | -2 | 20.67M | $403.69M | — | −2 |
| Q4 2024 | 13 | +2 | 16.59M | $411.47M | +3 | −1 |
| Q3 2024 | 10 | -1 | 11.89M | $291.41M | — | −1 |
| Q2 2024 | 11 | — | 12.82M | $300.27M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | ARK Investment Management ✦ | 8.48M | +20.0% | $165.62M | 1.7% | ▲ Add | 4 | SEC ↗ |
| 2 | State Street Global Advisors ✦ (passive) | 3.44M | +11.8% | $67.19M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | T. Rowe Price ✦ | 3.03M | +72.6% | $59.11M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | T. Rowe Price ✦ | 3.03M | +72.6% | $59.11M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | Citadel Advisors ✦ | 2.50M | +21.2% | $48.83M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 2.50M | +21.2% | $48.83M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | Geode Capital Management ✦ (passive) | 2.20M | +21.9% | $42.96M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | Geode Capital Management ✦ (passive) | 2.20M | +21.9% | $42.96M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 9 | Two Sigma Investments ✦ | 369.20K | +215.3% | $7.21M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 10 | Baillie Gifford ✦ | 302.73K | -1.8% | $5.91M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 11 | Baillie Gifford ✦ | 302.73K | -1.8% | $5.91M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 12 | Baillie Gifford ✦ | 302.73K | -1.8% | $5.91M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 13 | Marshall Wace ✦ | 269.13K | +389.3% | $5.26M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 14 | Marshall Wace ✦ | 269.13K | +389.3% | $5.26M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 15 | Millennium Management ✦ | 36.48K | -51.6% | $712,454 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 16 | Wellington Management ✦ | 33.63K | -5.5% | $656,814 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 17 | Wellington Management ✦ | 33.63K | -5.5% | $656,814 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 18 | Wellington Management ✦ | 33.63K | -5.5% | $656,814 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 19 | Wellington Management ✦ | 33.63K | -5.5% | $656,814 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 20 | Renaissance Technologies ✦ | 12.11K | -47.1% | $236,450 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Point72 Asset Management | $4.80M | was 0.0% |
| Norges Bank | $461,057 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 248 holders, 107.79M shares, $2.49B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.